2-(5-Thiophen-3-yltetrazol-1-yl)acetic acid;hydrate | 172041-28-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(5-Thiophen-3-yltetrazol-1-yl)acetic acid;hydrate
• CAS: 172041-28-0
• 化学式: C7H8N4O3S
• 分子量: 228.23
• InChiKey: MUUQBXLJEAHTND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.34
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• PROPHYLACTIC OR THERAPEUTIC MEDICATION FOR INNER EAR DISORDERS
  申请人：Sanwa Kagaku Kenkyusho Co., Ltd

  公开号：EP2565196A1

  公开（公告）日：2013-03-06

  A pharmaceutical for preventing or treating an inner ear disorder, comprising a spirohydantoin derivative represented by a general formula (I): in the formula, X represents a halogen atom or a hydrogen atom, and R1 and R2 simultaneously or individually represent a hydrogen atom or an optionally substituted C1-6 alkyl group, or a pharmacologically acceptable salt thereof as an active ingredient.

  一种预防或治疗内耳疾病的药物，由通式 (I) 所代表的螺海因衍生物组成： 式中，X 代表卤素原子或氢原子，R1 和 R2 同时或单独代表氢原子或任选取代的 C1-6 烷基、 或其药理上可接受的盐作为活性成分。
• 神経血流増加剤
  申请人：わかもと製薬株式会社

  公开号：JP2004099538A

  公开（公告）日：2004-04-02

  【課題】糖尿病合併症治療薬に関するものであり、アルドース還元酵素阻害活性および神経血流改善作用を併せ持つ化合物を提供すること。【解決手段】アルドース還元酵素阻害活性を持つ［５−（３−チエニル）テトラゾール−１−イル］　酢酸・一水和物；［５−（３−ｔｈｉｅｎｙｌ）ｔｅｔｒａｚｏｌ−１−ｙｌ］　ａｃｅｔｉｃ　ａｃｉｄ　ｍｏｎｏｈｙｄｒａｔｅを有効成分とする神経血流増加剤。本化合物はアルドース還元酵素阻害活性を有するが、著明な坐骨神経血流改善作用を併せ持つことにより糖尿病合併症の治療に有用である。【選択図】無し

  问题是要提供一种既具有醛糖还原酶抑制活性又具有改善神经血流作用的化合物。有效成分是[5-(3-噻吩基)四唑-1-基]乙酸一水合物，它具有醛糖还原酶抑制活性。该化合物具有醛糖还原酶抑制活性，但由于其明显的坐骨神经血流改善作用，可用于治疗糖尿病并发症。无。
• Medical devices to treat or inhibit restenosis
  申请人：Hezi-Yamit Ayala

  公开号：US20060062822A1

  公开（公告）日：2006-03-23

  Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of aldose reductase (AR) inhibitors are disclosed. Preferred AR inhibitors are enumerated. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the AR inhibitor with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-AR inhibitor blends are disclosed. Additionally, medical devices having a coating comprising at least one AR inhibitor in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.

  本研究公开了具有抗血管狭窄涂层的植入式医疗器械。具体而言，公开了具有醛糖还原酶（AR）抑制剂涂层的植入式医疗器械。本文列举了优选的 AR 抑制剂。抗血管再狭窄医疗器械包括支架、导管、微颗粒、探针和血管移植物。血管内支架是首选的医疗器械。这些医疗器械可以使用本领域已知的任何方法进行涂层，包括在涂覆前将 AR 抑制剂与生物相容性聚合物复合。此外，还公开了完全由生物相容性聚合物-AR 抑制剂混合物组成的医疗器械。此外，还公开了具有由至少一种 AR 抑制剂与至少一种额外治疗剂组合而成的涂层的医疗设备。此外，还公开了使用和制造抗再狭窄植入装置的相关方法。
• PHARMACEUTICAL FOR PREVENTING OR TREATING AN INNER EAR DISORDER
  申请人：Hara Akira

  公开号：US20130005698A1

  公开（公告）日：2013-01-03

  A pharmaceutical for preventing or treating an inner ear disorder, comprising a spirohydantoin derivative represented by a general formula (I): in the formula, X represents a halogen atom or a hydrogen atom, and R 1 and R 2 simultaneously or individually represent a hydrogen atom or an optionally substituted C 1-6 alkyl group, or a pharmacologically acceptable salt thereof as an active ingredient.